Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of glucagon-like peptide-1 receptor agonists on outcomes in knee osteoarthritis among persons with obesity has not been well studied. METHODS We conducted a 68-week, double-blind, randomized, placebo-controlled trial at 61 sites in 11 countries. Participants with obesity (a body-mass index [BMI; the weight in kilograms divided by the square of the height in meters] of ≥30) and a clinical and radiologic diagnosis of moderate knee osteoarthritis with at least moderate pain were randomly assigned, in a 2:1 ratio, to receive once-weekly subcutaneous semaglutide (2.4 mg) or placebo, in addition to counseling on physical activity and a reduced-calorie diet. The primary end points were the percentage change in body weight and the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score (on a scale of 0 to 100, with higher scores reflecting worse outcomes) from baseline to week 68. A key confirmatory secondary end point was the physical-function score on the 36-Item Short Form Health Survey (SF-36), version 2 (on a scale of 0 to 100, with higher scores indicating greater well-being). RESULTS A total of 407 participants were enrolled. The mean age was 56 years, the mean BMI 40.3, and the mean WOMAC pain score 70.9. A total of 81.6% of the participants were women. The mean change in body weight from baseline to week 68 was -13…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Semaglutide (2•4 mg/week) has been shown to cause symptomatic improvement related to moderate knee osteoarthritis as well as bodyweight reduction.89”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [89]
In the citing paper
“In a 68-week clinical trial involving individuals with obesity and knee osteoarthritis with moderate to severe pain (STEP-9), semaglutide treatment led to a greater reduction in the Western Ontario and McMaster Universities Osteoarthritis Index score (–41.7 points) as compared with placebo (–27.5 points) (88).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [88]
In the citing paper
“While the contribution of weight loss remains unclear, this study, alongside emerging preclinical data from rodent models, suggests that GLP-1 medicines may offer efficacy in inflammation-driven diseases independent of the amelioration of metabolic dysfunction.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [88]
In the citing paper
“In the STEP-9 trial, use of semaglutide led to greater weight loss and improvements in knee pain and physical function compared to placebo in patients with obesity and moderate-to-severe osteoarthritis-related symptoms.45”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [45]
In the citing paper
“In the STEP 9 trial involving adults with obesity and knee osteoarthritis, semaglutide resulted in significantly greater weight loss (− 13.7% vs. −3.2%), pain reduction (WOMAC − 41.7 vs. −27.5 points), and improvement in physical function (SF-36 + 12.0 vs. +6.5 points) compared to placebo (all P < 0.001) at 68 weeks, with a similar rate of serious adverse events [63].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [63]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Altman, R., Asch, E., Bloch, D., Bole, G., Borenstein, D., Brandt, K., Christy, W., Cooke, T. D., Greenwald, R., Hochberg, M., et al. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780290816 · Cited by 6,777
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationHunter, D. J., & Bierma-Zeinstra, S. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30417-9 · Cited by 4,795
OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis
Bannuru, R. R., Osani, M. C., Vaysbrot, E. E., Arden, N. K., Bennell, K., Bierma-Zeinstra, S. M. A., Kraus, V. B., Lohmander, L. S., Abbott, J. H., Bhandari, M., et al. (2019) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2019.06.011 · Cited by 3,542
Kolasinski, S. L., Neogi, T., Hochberg, M. C., Oatis, C., Guyatt, G., Block, J., Callahan, L., Copenhaver, C., Dodge, C., Felson, D., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24131 · Cited by 2,516
Classifications in Brief: Kellgren-Lawrence Classification of Osteoarthritis
Kohn, M. D., Sassoon, A. A., & Fernando, N. D. (2016) · Clinical Orthopaedics & Related Research · doi:10.1007/s11999-016-4732-4 · Cited by 1,459
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Self-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Tang, S., Zhang, C., Oo, W. M., Fu, K., Risberg, M. A., Bierma-Zeinstra, S. M., Neogi, T., Atukorala, I., Malfait, A.-M., Ding, C., et al. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00594-6 · Cited by 476
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“Rates of serious adverse events were similar in the two treatment arms, and a greater reduction in use of analgesic agents was reported in the semaglutide-treated subjects 121 .”
West, S., Scragg, J., Aveyard, P., Oke, J. L., Willis, L., Haffner, S. J. P., Knight, H., Wang, D., Morrow, S., Heath, L., et al. (2026) · BMJ · doi:10.1136/bmj-2025-085304 · Cited by 174
Osteoarthritis treatment via the GLP-1–mediated gut-joint axis targets intestinal FXR signaling
Yang, Y., Hao, C., Jiao, T., Yang, Z., Li, H., Zhang, Y., Zhang, W., Doherty, M., Sun, C., Yang, T., et al. (2025) · Science · doi:10.1126/science.adt0548 · Cited by 160
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
“…adverse cardiovascular events [22], decreased mortality in heart failure [23 – 27], and improvements in obstructive sleep apnea [21, 28], prediabetes [29, 30], chronic kidney disease [31], knee osteoarthritis [32], substance use disorders [33], and metabolic-associated steatotic liver disease [34].”
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
“45 However, the extent to which these benefits reflect weight loss vs. direct anti-inflammatory or structural effects remains unclear, as the trial did not assess imaging or biochemical markers of joint degeneration.”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“…adverse cardiovascular events [23], decreased mortality in heart failure [24 – 28], and improvements in obstructive sleep apnea [12,29], prediabetes [30,31], chronic kidney disease [32], knee osteoarthritis [33], substance use disorders [34], and metabolic-associated steatotic liver disease [35].”
Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Deanfield, J., Lincoff, A. M., Kahn, S. E., Emerson, S. S., Lingvay, I., Scirica, B. M., Plutzky, J., Kushner, R. F., Colhoun, H. M., Hovingh, G. K., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01375-3 · Cited by 143
Wharton, S., Freitas, P., Hjelmesæth, J., Kabisch, M., Kandler, K., Lingvay, I., Quiroga, M., Rosenstock, J., & Garvey, W. T. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00226-8 · Cited by 119
Self-citationNauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Wong, C. K., & Drucker, D. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194751 · Cited by 112
McGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Sbraccia, P., Martinez-Tellez, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03978-z · Cited by 100
“Semaglutide 47 and liraglutide 27 were assessed in patients with obesity and knee osteoarthritis (KOA).”
13. Older Adults: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s013 · Cited by 87
Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update
Pedersen, S. D., Manjoo, P., Dash, S., Jain, A., Pearce, N., & Poddar, M. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.250502 · Cited by 78
Obesity: Recent Advances and Future Perspectives
Janić, M., Janež, A., El‐Tanani, M., & Rizzo, M. (2025) · Biomedicines · doi:10.3390/biomedicines13020368 · Cited by 97
“Recently, the administration of semaglutide at a weekly dose of 2.4 mg was also associated with a significant reduction in body weight and alleviation of pain in individuals with obesity and radiologically confirmed moderate knee osteoarthritis [20].”
InfluentialOsteoarthritis year in review 2025: Epidemiology and therapy
Dell’Isola, A., Recenti, F., Giardulli, B., Lawford, B. J., & Kiadaliri, A. (2025) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2025.08.015 · Cited by 71
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 82
“Benefits of semaglutide have also been identified in people with a variety of other cardiometabolic and linked conditions, including metabolic liver disease 27 , diabetic kidney disease 28 , knee osteoarthritis 29 and peripheral artery disease 30 .”
The effects of GLP-1 agonists on musculoskeletal health and orthopedic care
Gatto, A., Liu, K., Milan, N., & Wong, S. (2025) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-025-09978-3 · Cited by 55
Quarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., & Quarenghi, R. T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113791 · Cited by 65
Xie, X., Zhang, K., Li, Y., Li, Y., Li, X., Lin, Y., Huang, L., & Tian, G. (2025) · PLoS ONE · doi:10.1371/journal.pone.0324296 · Cited by 62
Osteoarthritis as a systemic disease
Collins, K. H., Haugen, I. K., Neogi, T., & Guilak, F. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01332-8 · Cited by 83
“OA is a serious disease; it increases the prevalence of other chronic diseases that directly reduce healthspan, and contributes to walking disability, which is associated with mortality 26,32,33 .”
Sattar, N. A., & Lee, M. M. Y. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00363-2 · Cited by 58
Bılgın, E., Venerito, V., & Bogdanos, D. P. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103864 · Cited by 57
Tirzepatide for overweight and obesity management
Hamza, M., Papamargaritis, D., & Davies, M. J. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2436595 · Cited by 43
“…without T2D) semaglutide 2.4 mg improved the symptoms, physical limitations and exercise function compared to placebo, while in people with obesity and knee osteoarthritis improved the WOMAC pain score, a widely used tool to assess pain, stiffness and function in people with osteoarthritis [72,73].”
InfluentialCarbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70059 · Cited by 57
O'Keefe, J. H., Franco, W. G., & O'Keefe, E. L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.12.010 · Cited by 42
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Salvador, R., Moutinho, C. M. S. G., Sousa, C., Vinha, A. F., Carvalho, M. C., & Matos, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18030399 · Cited by 55
“The research demonstrated that the percentage reduction in body weight was significantly higher with SMG compared to placebo [106].”
Madsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“In patients with obesity and knee osteoarthritis ( n = 4079, BMI 40.3 kg/m 2 ), semaglutide 2.4 mg OW reduced body weight with −13.7% and −3.2% with placebo, which resulted in significantly greater pain relief related to knee osteoarthritis compared with placebo [52].”
InfluentialThe potential role of GLP ‐1 receptor agonists in osteoarthritis
Ryan, M., Megyeri, S., Nuffer, W. A., & Trujillo, J. M. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70005 · Cited by 47
“55 The results of the STEP-9 trial align with the results of the Shanghai Osteoarthritis Cohort study, where greater reductions in pain scores were seen in participants with T2D and KOA taking a GLP-1 RA.”
The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies
Haberman, R. H., Ogdie, A., Merola, J. F., Scher, J. U., & Eder, L. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01326-6 · Cited by 51
“In the STEP 9 trial, once-weekly treatment with semaglutide was associated with considerable reduction in body weight and pain related to knee osteoarthritis 211 .”
Advances in GLP-1 receptor agonists for pain treatment and their future potential
He, Y., Xu, B., Zhang, M., Chen, D., Wu, S., Gao, J., Liu, Y., Zhang, Z., Kuang, J., & Fang, Q. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-01979-4 · Cited by 46
Giblin, K., Kaplan, L. M., Somers, V. K., Le Roux, C. W., Hunter, D. J., Wu, Q., Lalonde, A., Ahmad, N., & Bethel, M. A. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70209 · Cited by 34
“8,9 In dedicated trials in participants with specific complications of obesity, such as T2D, CVD, OSA and OA, weight reduction from therapies that include GLP-1 receptor agonist activity has generally been less than that seen in general obesity trials of the same agents.”
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Gonzalez-Rellan, M. J., Riobello, C., Fang, S., da Silva, E. M., Koehler, J. A., Shang, R., Hammoud, R., Cao, X., Varela‐Rey, M., & Drucker, D. J. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.03.011 · Cited by 47
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 41
“Adverse events (primarily gastrointestinal disorders) leading to discontinuation of the trial regimen occurred in 6.7 % of the participants in the treatment group and in 3.0 % in the placebo group [102] 6.6.”
InfluentialSynovial fluid as a complex molecular pool contributing to knee osteoarthritis
Peters, H., Rockel, J. S., Little, C. B., & Kapoor, M. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01271-4 · Cited by 43
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28
Cheng, J., Solomon, T., Estee, M. M., Cicuttini, F., & Lim, Y. Z. (2025) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2025.100567 · Cited by 33
The expanding benefits of GLP-1 medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102214 · Cited by 42
Treating sarcopenic obesity in the era of incretin therapies: perspectives and challenges
Chen, A. S., & Batsis, J. A. (2025) · Diabetes · doi:10.2337/dbi25-0004 · Cited by 32
Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions
Karacabeyli, D., & Lacaille, D. V. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01302-0 · Cited by 34
“After the initial improvement, mean KOOS pain score (0–100, with 100 representing no pain) at randomization was 78, leaving limited room for further improvement.”
InfluentialTuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
Sarcopenic obesity and weight loss-induced muscle mass loss
Caturano, A., Amaro, A., Berra, C., & Conte, C. (2025) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001131 · Cited by 73
“Similarly, in the STEP 9 trial, individuals with obesity and knee osteoarthritis treated with semaglutide experienced approximately 14% weight loss and demonstrated better functional capacity at study end [48].”
Ostrominski, J. W., Ortega-Montiel, J., Tesfaye, H., ALIX, C., DiCesare, E., CROMER, S. J., Wexler, D. J., Paik, J. M., & Patorno, E. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02870 · Cited by 29
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J. P., Butsch, W. S., Christensen, S. M., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2026.100269 · Cited by 41
Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis
Kellner, D. A., Dente, E., Tran, V., Welsh, T., Tran, V., Saha, A., Baker, J. F., Elashoff, D. A., & Ranganath, V. K. (2025) · ACR Open Rheumatology · doi:10.1002/acr2.70103 · Cited by 27
Qin, H., Yu, J., Yu, H., Zhou, C., Yuan, D., Wang, Z., Zhu, Z., Wei, G., Ou, P., Li, Z., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.01.008 · Cited by 30
Sabatella, L., Ortega, P., Valentí, V., Rotellar, F., Pagola, A. U., Ahmed, A., Purkayastha, S., Tuero, C., Blanco, N., & Landecho, M. F. (2025) · Obesity · doi:10.1002/oby.70100 · Cited by 32
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
“In the STEP-9 trial, once-weekly semaglutide (2.4 mg) was evaluated for its effects on obesity and knee osteoarthritis pain in 407 participants over 68 weeks [122].”
InfluentialProkopidis, K. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70355 · Cited by 29
Langer, H. T., Gilmore, N. K., Hayden, C. M. T., Roux, J., Bariohay, B., Rouquet, T., Awada, M., Marcotorchino, J., Bournot, L., Nunn, E., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102665 · Cited by 21
“42 Similar findings were reported by the SLIM LIVER study, where trends toward improved gait speed were found despite a decrease in psoas muscle volume.”
Huang, S., Chen, J., Zhang, H., Wu, W., Xue, S., Zhu, Z., & Ding, C. (2025) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2025.100614 · Cited by 23
Pennings, N. J., Varney, C., Hines, S., Riley, B. A., Happel, P., Patel, S., & Bays, H. E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100172 · Cited by 25
“The excessive load on knee joints due to obesity may induce stress and malalignment that contributes to osteoarthritis; weight reduction has the potential to reduce knee pain among patients with obesity [55].”
Self-citationThe Vicious Cycle of Obesity and Low Back Pain: A Comprehensive Review
Ruiz‐Fernández, C., Schol, J., Ambrosio, L., & Sakai, D. (2025) · Applied Sciences · doi:10.3390/app15126660 · Cited by 25
Buonanno, S., Gaggiano, C., Terribili, R., Cantarini, L., Frediani, B., & Gentileschi, S. (2025) · Inflammation Research · doi:10.1007/s00011-025-02140-2 · Cited by 23
Spreckley, M., Ruggiero, C. F., & Brown, A. (2026) · Obesity Reviews · doi:10.1111/obr.70079 · Cited by 16
Siebert, S., Sattar, N. A., & Ferguson, L. D. (2025) · Joint Bone Spine · doi:10.1016/j.jbspin.2025.105904 · Cited by 21
Betensky, D. J., Smith, K. C., Katz, J. N., Yang, C. J., Hunter, D. J., Collins, J. E., Feldman, C. H., Messier, S. P., Kim, J., Selzer, F., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03609 · Cited by 20
Timofte, D. V., Tudor, R. C., Mocanu, V., & Labusca, L. S. (2024) · Nutrients · doi:10.3390/nu16234231 · Cited by 16
Christensen, S. M., & Nelson, C. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100175 · Cited by 21
“Other obesity trials of semaglutide and tirzepatide show clinical improvement for adults with conditions such as heart failure [97 – 100], prediabetes [74,101,102], and knee osteoarthritis [103].”
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“…failure with preserved ejection fraction (HFpEF) (STEP-HFpEF trial) [25], reduced pain and analgesics use in knee osteoarthritis (STEP-9 trial) [26], and demonstrated histological benefits in metabolic dysfunction-associated steatohepatitis (MASH) (ESSENCE trial) [27], leading to Food and Drug…”
Semaglutide for adults living with obesity
Bracchiglione, J., Meza, N., Franco, J. V. A., Liquitay, C. M. E., Victoria Novik, A., Vargas, M. O., Lazcano, G., Poloni, D., Langlotz, F. R., Figuls, M. R. I., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015092.pub2 · Cited by 36
Musculoskeletal disease in acromegaly—a population-based registry study
Rosendal, C., Arlien-Søborg, M. C., Nielsen, E. H., Feltoft, C. L., Rasmussen, Å. K., Andersen, M., Jørgensen, J. O. L., & Dal, J. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf047 · Cited by 13
Ceron, E. L., Reddy, S. D., Kattamuri, L. P. V., Muvva, D. M., Chozet, L. E., & Bright, T. M. (2025) · Journal of Brown Hospital Medicine · doi:10.56305/001c.132255 · Cited by 20
Barrea, L., Annunziata, G., Verde, L., Galasso, M., Savastano, S., Colao, A. A. L., & Muscogiuri, G. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00667-3 · Cited by 26
Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
Gudzune, K. A., Apovian, C. M., Aroda, V. R., Aronne, L. J., Balapattabi, K., Bennett, A. K., ChallaSivaKanaka, S., ElSayed, N. A., Fitch, A., Fitzpatrick, S. L., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0008 · Cited by 27
Therapeutic strategies targeting synovial cells to treat osteoarthritis
Li, F., Venkatesan, J. K., Madry, H., & Cucchiarini, M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118317 · Cited by 14
Effect of GLP1 Agonists on Reproduction
Couldwell, M., Tidwell, A. J., & Taylor, A. E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf401 · Cited by 16
Anker, S. D., Ji, L., Kindel, T., Coats, A. J. S., Ojji, D., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2025) · Global Cardiology · doi:10.4081/cardio.2025.86 · Cited by 17
Glucagon-like peptide-1 medicines and cancer
Yabut, J. M., & Drucker, D. J. (2026) · Nature Cancer · doi:10.1038/s43018-025-01110-1 · Cited by 15
“https://doi.org/10.1038/s43018-025-01110-1 of metabolic liver disease and osteoarthritis 20,21 , whereas tirzepatide ameliorates metabolic liver disease 22 and improves symptoms and outcomes in people with obstructive sleep apnea 23 .”
InfluentialThe evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“In osteoarthritis, semaglutide use has been associated with lower risk of knee replacement 288 , and retatrutide has also shown clinically meaningful improvements in knee pain and physical function in a dedicated phase III trial 181 .”
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
Babazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 16
“%) measured BW changes as the primary outcome [6 – 8, 10,12,13, 23 – 27”
Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
C, K. A. C. M. V. R. L. J. K. A. G. A. A. A. B. B. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005729 · Cited by 36
“49 Emerging data suggest that ≥ 15% wt reduction may be needed to achieve clinical benefits in some cases, 45 particularly for individuals with moderate- to-severe obesity-related conditions.”
InfluentialSingh, A., Singh, A. K., Singh, R., & Misra, A. (2025) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103212 · Cited by 13
Wadden, T., Oquendo, M. A., Kushner, R. F., Cao, D., Karanikas, C. A., Kechter, A., & Murphy, M. A. (2026) · Obesity · doi:10.1002/oby.70122 · Cited by 16
Alhomoud, I. S., Wheeler, S. E., & Dixon, D. L. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0038 · Cited by 14
Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program
Makam, A. N., Bailey, L. R. J., Anderson, N., Bellitti, K., Skinner, S., & Nguyen, O. K. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01449 · Cited by 10
The expanding role of semaglutide: beyond glycemic control
Zarei, M., Sabetkasaei, M., Mozafari, M., & Zaeri, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01663-z · Cited by 11
“Once in the CNS, semaglutide”
GLP-1 agonists: a game changer in pain treatment and addiction
Bade, S., Hurdle, M. F. B., Bade, S., Encalada, S., Kanahan-Osman, S., & Gupta, S. (2025) · Pain Management · doi:10.1080/17581869.2025.2536998 · Cited by 12
Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies
Xu, Y., Drucker, D. J., Traverso, G., & Beloqui, A. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf027 · Cited by 12
Pain mechanisms in osteoarthritis: recent discoveries and opportunities ahead
Hoffman, D. B., Miller, R. E., & Malfait, A. (2025) · Connective Tissue Research · doi:10.1080/03008207.2025.2531414 · Cited by 9
“Indeed, in clinical OA patients, both the Shanghai Osteoarthritis Cohort study and STEP 9 trial reported significantly reduced pain scores in those receiving GLP-1 RAs compared to placebo or those without treatment 33,34 .”
Seddio, A. E., Vasudevan, R. S., Gouzoulis, M. J., Ansah-Twum, J. K., Grauer, J. N., & Rubin, L. E. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.08.003 · Cited by 14
Troshina, E. A., Antsiferov, M. B., As, A., Galstyan, G. R., Маркова, Т. Н., Romantsova, T. I., Mazurina, N. V., & Koteshkova, O. M. K. (2025) · Problems of Endocrinology · doi:10.14341/probl13677 · Cited by 14
Moiz, A., Peters, T. M., Tsoukas, M. A., Yu, O. H. Y., Filion, K. B., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103991 · Cited by 15
“…outcomes, GLP-1 RAs show potential benefits across metabolic comorbidities, including metabolic dysfunction-associated steatotic liver disease, 17–19 obstructive sleep apnea, 20 knee osteoarthritis, 21 and polycystic ovary syndrome, 22–24 though durability of response requires longer-term data.”
Gholami, M., Balajam, N. Z., Rakhsha, S. S., Sajjadi‐Jazi, S. M., Shafiee, G., & Heshmat, R. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01604-w · Cited by 9
“Additionally, a randomized controlled trial found that semaglutide improves physical function and reduces WOMAC pain scores in patients with obese knee OA [50 ].”
Fu, W., Lin, J., You, C., Zhang, J., Lei, J., Zheng, L., Zheng, B., Liu, M., Liu, L., & Li, N. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16581 · Cited by 8
Tan, M., Shi, C., Chi, G., Su, X., Liu, F., Zhu, L., Cheng, G., Chen, X., Meng, Y., Chen, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202506841 · Cited by 9
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Sillassen, C. D. B., Petersen, J. J., Faltermeier, P., Yucel, D., Siddiqui, F., Andersen, R. K., Graever, L., Bjerg, J. L., Kamp, C. B., Grand, J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04486-0 · Cited by 10
“Non-serious adverse events were reported as outcomes in 45 trials [33–41, 43–46, 48–56, 58–67, 69–73, 75–79, 81, 82].”
Jansson, A. K., Gómez‐Martín, M., Hedin, L. E., Clarke, E. D., Cross, V., Stanford, J., Taylor, R., Bogl, L. H., de Vlieger, N., Koochek, A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70077 · Cited by 13
Li, M., Xu, S., Cai, H., Xiao, J., & Qin, Y. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156547 · Cited by 9
Koufakis, T., Kokkinos, A. D., & le Roux, C. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70723 · Cited by 9
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
Sheth, S., Merola, J. F., Weber, B. N., Prussick, R. B., Yeung, J., Liu, C., Glick, B. P., Reddy, S. M., Cook-Bolden, F. E., Wallace, E. B., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.0859 · Cited by 17
Glucagon-Like Peptide-1 Receptor Agonists and Osteoarthritis
Felson, D. T. (2024) · New England Journal of Medicine · doi:10.1056/nejme2409972 · Cited by 9
Beyond wear and tear at the joint
Liu, C.-J. (2025) · Science · doi:10.1126/science.adw4656 · Cited by 10
Jiang, G., Yang, X., Zhu, G., & Liu, T. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03017-4 · Cited by 10
Zheng, M., Zhao, J., Wang, Y., Cui, Z., Qiao, Z., Wu, H., Shi, C., & Wang, X. (2025) · Medicine · doi:10.1097/md.0000000000043239 · Cited by 9
Alibilli, A. S., Jain, V., Mane, H., Yue, X., Ratzki‐Leewing, A. A., Merchant, J. S., Criss, S., Nguyen, Q. C., McCoy, R. G., & Nguyen, T. T. X. (2025) · JMIR Infodemiology · doi:10.2196/73619 · Cited by 11
“Joint pain was an additional adverse event that appeared on social media but is not yet attributed to these medications in clinical trials [38].”
Metadata
- Authors
- Bliddal, H., Bays, H., Czernichow, S., Uddén Hemmingsson, J., Hjelmesæth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Vélez Sánchez, P., Wharton, S., Wizert, A., & Kristensen, L. E.
- Affiliations
- University of Louisville (US)
- From the Parker Institute, Copenhagen University Hospital at Bispebjerg and Frederiksberg, Copenhagen (H. Bliddal, L.E.K.), and Novo Nordisk, Søborg (T.H.M., A.K., J.S.N., A.W.) — both in Denmark; Louisville Metabolic and Atherosclerosis Research Center, University of Louisville School of Medicine, Louisville, KY (H. Bays); the Department of Nutrition, Hôpital Européen Georges Pompidou, Assistance Publique–Hôpitaux de Paris, Université Paris Cité, Paris (S.C.); the Obesity Department, Capio St. Göran’s Hospital, and Medical Department at the Karolinska Institute, Stockholm (J.U.H.); the Department of Endocrinology, Obesity, and Nutrition, Vestfold Hospital Trust, Tønsberg, and the Department of Endocrinology, Morbid Obesity, and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, Oslo — both in Norway (J.H.); Centro de Investigación en Reumatología y Especialidades Médicas, Bogota, Colombia (P.V.S.); and the University of Toronto and York University, Toronto, McMaster University, Hamil...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-31
- Volume
- 391
- Issue
- 17
- Pages
- 1573-1583
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4403912607
- Cited by
- 440
- References
- 37
- Citations by year
- 2026: 235 · 2025: 197 · 2024: 8
- FWCI
- 141.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
- Keywords
- semaglutide, knee osteoarthritis, obesity, GLP-1 receptor agonists, weight loss, osteoarthritis pain, physical function, hypocaloric diet, physical activity counseling, adverse events, serious adverse events, drug safety, quality of life, Western Ontario and McMaster Universities Osteoarthritis Index, SF-36
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Combined Modality Therapy, Counseling, Double-Blind Method, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Pain Measurement, Weight Loss, Body Mass Index, Arthralgia, Osteoarthritis, Knee, Caloric Restriction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.